Evidence map›Paper›PMID 34302010›Full record

ArticleScientific reports2021

Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.

Michael A Kiebish, Poornima Tekumalla, Shobha Ravipaty, Albert Dobi, Shiv Srivastava, Wenfang Wu, Saurabh Patil, Tracey Friss, Allison Klotz, Alagarsamy Srinivasan and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Michael A KiebishBERG, 500 Old Connecticut Path, Building B, Framingham, MA, 01701, USA.
Poornima TekumallaBERG, 500 Old Connecticut Path, Building B, Framingham, MA, 01701, USA.
Shobha RavipatyBERG, 500 Old Connecticut Path, Building B, Framingham, MA, 01701, USA.
Albert DobiCenter for Prostate Disease Research, John P. Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, MD, 20817, USA.
Shiv SrivastavaCenter for Prostate Disease Research, John P. Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, MD, 20817, USA.
Wenfang WuBERG, 500 Old Connecticut Path, Building B, Framingham, MA, 01701, USA.
Saurabh PatilBERG, 500 Old Connecticut Path, Building B, Framingham, MA, 01701, USA.
Tracey FrissBERG, 500 Old Connecticut Path, Building B, Framingham, MA, 01701, USA.
Allison KlotzBERG, 500 Old Connecticut Path, Building B, Framingham, MA, 01701, USA.
Alagarsamy SrinivasanCenter for Prostate Disease Research, John P. Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, MD, 20817, USA.
Jennifer CullenCenter for Prostate Disease Research, John P. Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, MD, 20817, USA.
Inger L RosnerCenter for Prostate Disease Research, John P. Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, MD, 20817, USA.
Amina AliCenter for Prostate Disease Research, John P. Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, MD, 20817, USA.
Sandra LaszloUniversity Health Network, Toronto, ON, M5G 2C4, Canada.
Michele PetrovicUniversity Health Network, Toronto, ON, M5G 2C4, Canada.
Neil FleshnerUniversity Health Network, Toronto, ON, M5G 2C4, Canada.
Jeonifer GarrenBERG, 500 Old Connecticut Path, Building B, Framingham, MA, 01701, USA.
Greg MillerBERG, 500 Old Connecticut Path, Building B, Framingham, MA, 01701, USA.
Nischal Mahaveer ChandBERG, 500 Old Connecticut Path, Building B, Framingham, MA, 01701, USA.
Leonardo O RodriguesBERG, 500 Old Connecticut Path, Building B, Framingham, MA, 01701, USA.
Elder GrangerBERG, 500 Old Connecticut Path, Building B, Framingham, MA, 01701, USA.
Mark D KelloggBERG, 500 Old Connecticut Path, Building B, Framingham, MA, 01701, USA.
Shen LuanBERG, 500 Old Connecticut Path, Building B, Framingham, MA, 01701, USA.
Eleftherios DiamandisMount Sinai Hospital, Toronto, ON, M5T 3L9, Canada.
Viatcheslav R AkmaevBERG, 500 Old Connecticut Path, Building B, Framingham, MA, 01701, USA.
Rangaprasad SarangarajanBERG, 500 Old Connecticut Path, Building B, Framingham, MA, 01701, USA.
Chas BountraDepartment of Clinical Medicine, University of Oxford, Oxford, OX3 7LF, UK.
Stephen J FreedlandCenter for Integrated Research in Cancer and Lifestyle, Cedar-Sinai, Los Angeles, CA, 90048, USA.
David G McLeodCenter for Prostate Disease Research, John P. Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, MD, 20817, USA.
Niven R NarainBERG, 500 Old Connecticut Path, Building B, Framingham, MA, 01701, USA. Niven.Narain@berghealth.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate-specific antigen (PSA) screening for prostate cancer (PCa) is limited by the lack of specificity but is further complicated in the benign prostatic hyperplasia (BPH) population which also exhibit elevated PSA, representing a clear unmet need to distinguish BPH from PCa. Herein, we evaluated the utility of FLNA IP-MRM, age, and prostate volume to stratify men with BPH from those with PCa. Diagnostic performance of the biomarker panel was better than PSA alone in discriminating patients with negative biopsy from those with PCa, as well as those who have had multiple prior biopsies (AUC 0.75 and 0.87 compared to AUC of PSA alone 0.55 and 0.57 for patients who have had single compared to multiple negative biopsies, respectively). Of interest, in patients with PCa, the panel demonstrated improved performance than PSA alone in those with Gleason scores of 5-7 (AUC 0.76 vs. 0.56) and Gleason scores of 8-10 (AUC 0.74 vs. 0.47). With Gleason scores (8-10), the negative predictive value of the panel is 0.97, indicating potential to limit false negatives in aggressive cancers. Together, these data demonstrate the ability of the biomarker panel to perform better than PSA alone in men with BPH, thus preventing unnecessary biopsies.

Indexed as

Diagnosis, DifferentialAgedBiomarkers, TumorHumansMaleMiddle AgedNeoplasm GradingProstateProstate-Specific AntigenProstatic HyperplasiaProstatic NeoplasmsBiomarkers, TumorProstate-Specific Antigen

Identifiers

PMID34302010
PMCPMC8302659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.